PKC-activating compounds for the treatment of neurodegenerative diseases
AssigneeCognitive Research Enterprises, Inc.
InventorsThomas J. Nelson, Daniel L. Alkon
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Claims8
A compound of a formula
- wherein R is an alkyl, or a pharmaceutically acceptable salt thereof.
A compound of a formula
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising methyl-3-(2-((2-((2-((2-((2-((2-ethylcyclopropyl)methyl)cyclopropyl)methy-1)cyclopropyl)methyl)-cyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)propanoate or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method of activating an epsilon isoform of protein kinase C in a patient in need thereof comprising administering an effective amount of a compound of formula
- or a pharmaceutically acceptable salt thereof.
A method of treating a neurological disease selected from the group consisting of Alzheimer's disease, multiple sclerosis, and stroke comprising administering to a patient in need thereof methyl-3-(2-((2-((2-((2-((2-((2-ethylcyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)methyl)-cyclopropyl)methyl)cyclopropyl)methyl)cyclopropyl)propanoate or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.